High Prevalence of Foodborne Diseases is expected to drive the Growth of the Market

It has been witnessed over the years that there was an increase in the prevalence of foodborne infections caused by food deterioration. As per the World Health Organization (WHO), more than 600 million people will become ill, and 420,000 will die due to contaminated food in 2019, leading to the loss of 33 million healthy life years (DALYs). Increasing demand from the Asia-Pacific and growing incidence of osteoporosis are anticipated to boost the market's growth.

Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/global-bacteriophages-therapy-market

Data Bridge Market Research analyses that the Global Bacteriophages Therapy Market was valued at USD 39.80 million in 2021 and is expected to reach USD 64.40 million by 2029, registering a CAGR of 6.20% during the forecast period of 2022 to 2029. The increasing demand for bacteriophages therapy will provide potential opportunities for the market growth in the forecast period.  

The increasing prevalence of antibiotic-resistant infections is anticipated to drive the market's growth rate

The increase in antibiotic-resistant infections is because of the overuse of antibiotics and other factors. The increase in antibiotic-resistant infections would surge the collaborations between market players. That would lead to the rise in investments and funds being granted by several public-private organizations and government organizations. For instance, per the CDC statistics, every year in the U.S., at least 2.8 million people get an antibiotic-resistant infection, and more than 35,000 people die.

Report Scope and Market Segmentation

Segment Analysis:  

Global bacteriophages therapy market is categorized into seven notable segments which are based on target, type, base, application, route of administration, end-user and distribution channel.

• On the basis of target, global bacteriophages therapy market is segmented into escherichia coli, staphylococcus, streptococcus, pseudomonas, salmonella, others.

The staphylococcus segment of target type is anticipated to dominate the telehealth market

The staphylococcus segment is expected to dominate the global bacteriophages therapy market with 27.22% market share as this species is the most common bacterial species causing infection

• On the basis of type, global bacteriophages therapy market is segmented into lytic & lysogenic.

The lytic segment of type is anticipated to dominate the telehealth market

The lytic segment is expected to dominate the global bacteriophages therapy market with 92.06% market share due to the instant recovery and therapeutic effect provided by this type of lytic bacteriophage

• On the basis of base, global bacteriophages therapy market is segmented into sterile broth culture & water-soluble jelly base. The sterile broth culture segment is expected to dominate the global bacteriophages therapy market with 70.60% market share as the bacteriophage cultured at different oxygen levels in sterile broth and more specificity towards the bacteriophages is provided in broth culture.
• On the basis of application, the global bacteriophages therapy market is segmented into bacterial dysentery, infection of skin & nasal mucosa, suppurative skin infections, lung and pleural infections, post-operative wound infections, and others. The post-operative wound segment is expected to dominate the global bacteriophages therapy market with 34.47% market share because of the number of open surgeries and accidental cases that take place around the world
• On the basis of route of administration, global bacteriophages therapy market is segmented into oral, parenteral, rectal, dermal, others. The oral segment is expected to dominate the global bacteriophages therapy market with 45.62% market share due to the increasing focus on the development of new administration techniques out of which oral is the effective and patient convenient route of administration for bacteriophages.
• On the basis of end user, the global bacteriophages therapy market is segmented into hospitals, specialty clinics, academic research & institutes, and others. The hospitals segment is expected to dominate the global bacteriophages therapy market with 38.25% market share due to the increasing emphasis on bacteriophages therapy, partnerships with numerous research institutes for clinical trials
• On the basis of distribution channel, the global bacteriophages therapy market is segmented into direct tender and third-party distributors. The direct tender segment is expected to dominate the global bacteriophages therapy market with 90.44% market share because of a larger number of market players and the geographical presence of these players

Major Players

Data Bridge Market Research recognizes the following companies as the major bacteriophages therapy market players in bacteriophages therapy market are Microgen (U.S.), ATCC (U.S.), Intralytix, Inc. (U.S.), Adaptive Phage Therapeutics (U.S.), Armata pharmaceuticals Inc. (U.S.),LOCUS BIOSCIENCES, INC. (U.S.), Delmont Laboratories, Inc. (U.S.), Nextbiotics (U.S.), Pherecydes Pharma (France), iNtODEWORLD. Inc. (U.S.), Enbiotix (U.S.), Fixed-Phage Limited (U.K.), Cytophage Technologies Inc. (Canada), Phagelux, Inc. (China), TechnoPhage (Portugal), Eligo Bioscience SA (France), BiomX Ltd. (Israel).

Market Development

• In 2021, Armata Pharmaceuticals, Inc. announced an investment of USD 20 million to support the advancement of Bacteriophage development programs the company. The company further announced that it has agreed with Innoviva Strategic Opportunities LLC to sell Armata common stock and warrant securities.
• In 2020, Phagelux Inc. announced that it has entered into multiple commercial collaborations such as European sales, marketing, and product development collaboration with DCM for its AgriPhage line of biopesticides, among others.

Regional Analysis

Geographically, the countries covered in the bacteriophages therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

As per Data Bridge Market Research analysis:

North America is the dominant region in bacteriophages therapy market during the forecast period 2022 to 2029

North America dominates the bacteriophages therapy market due to the fast recovery and therapeutic effect provided by lytic bacteriophage, and rising healthcare expenditure will further boost the market's growth rate in this region. Furthermore, the presence of major market players and the increase in adoption of newer technologies will prompt the market's growth rate in this region.  

Asia-Pacific is estimated to be the fastest-growing region in bacteriophages therapy market the forecast period 2022 to 2029

Asia-Pacific is expected to grow during the forecast period of 2022 to 2029 because of growing investment in innovative R&D for novel drug products in this region. Furthermore, the development of healthcare infrastructure and increasing government initiatives will further boost the market's growth rate in this region.

For more detailed information about bacteriophages therapy market report, click here – https://www.databridgemarketresearch.com/fr/reports/global-bacteriophages-therapy-market